{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T23:52:28Z","timestamp":1773964348675,"version":"3.50.1"},"reference-count":76,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.hoc.2025.12.008","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T20:35:27Z","timestamp":1770669327000},"page":"303-319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cellular and Novel Immunotherapies for Classic Hodgkin Lymphoma"],"prefix":"10.1016","volume":"40","author":[{"given":"Daniel Klein","family":"Reef","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie Sophia","family":"Grover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.hoc.2025.12.008_bib1","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2025.12.008_bib2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2025.12.008_bib3","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1182\/hematology.2023000450","article-title":"The optimal management of relapsed and refractory Hodgkin lymphoma: post\u2013brentuximab and checkpoint inhibitor failure","volume":"2023","author":"Grover","year":"2023","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.hoc.2025.12.008_bib4","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/hematology.2024000575","article-title":"When to use stem cell transplantation for classical Hodgkin lymphoma","volume":"2024","author":"Perales","year":"2024","journal-title":"Hematology"},{"issue":"3","key":"10.1016\/j.hoc.2025.12.008_bib5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/14728214.2024.2349083","article-title":"Emerging immunotherapies in the Hodgkin lymphoma armamentarium","volume":"29","author":"Spinner","year":"2024","journal-title":"Expet Opin Emerg Drugs"},{"issue":"6","key":"10.1016\/j.hoc.2025.12.008_bib6","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.hoc.2023.05.017","article-title":"Chimeric antigen receptor T cells in hodgkin and T-Cell lymphomas","volume":"37","author":"Muhsen","year":"2023","journal-title":"Hematol Oncol Clin N Am"},{"issue":"7","key":"10.1016\/j.hoc.2025.12.008_bib7","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood-2006-11-059139","article-title":"Epstein Barr virus\u2013specific cytotoxic T lymphocytes expressing the anti-CD30\u03b6 artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease","volume":"110","author":"Savoldo","year":"2007","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2025.12.008_bib8","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1084\/jem.20040890","article-title":"Cytotoxic T lymphocyte therapy for Epstein-Barr Virus+ Hodgkin\u2019s disease","volume":"200","author":"Bollard","year":"2004","journal-title":"J Exp Med"},{"issue":"8","key":"10.1016\/j.hoc.2025.12.008_bib9","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2007-05-091280","article-title":"Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer","volume":"110","author":"Bollard","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2025.12.008_bib10","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor\u2013redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J Clin Investig"},{"issue":"32","key":"10.1016\/j.hoc.2025.12.008_bib11","first-page":"3794","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin Lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J Clin Orthod"},{"issue":"5","key":"10.1016\/j.hoc.2025.12.008_bib12","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1016\/S2352-3026(24)00064-4","article-title":"Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30+ lymphoma: a phase 1 study","volume":"11","author":"Grover","year":"2024","journal-title":"Lancet Haematol"},{"issue":"S2","key":"10.1016\/j.hoc.2025.12.008_bib13","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/hon.3164_388","article-title":"Combined autologous CD30.CAR-T cells and nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma after failure of frontline therapy (ACTION study)","volume":"41","author":"Ahmed","year":"2023","journal-title":"Hematol Oncol"},{"issue":"16","key":"10.1016\/j.hoc.2025.12.008_bib14","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1182\/blood.2024026758","article-title":"HSP-CAR30 with a high proportion of less-differentiated T cells promotes durable responses in refractory CD30+ lymphoma","volume":"145","author":"Caballero","year":"2025","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2025.12.008_bib15","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory hodgkin lymphoma: an open-label phase I trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.hoc.2025.12.008_bib16","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/bloodadvances.2023011470","article-title":"Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial","volume":"8","author":"Brudno","year":"2024","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.12.008_bib17","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1182\/blood-2024-200932","article-title":"CD30.CAR-T cells Co-Expressing the CCR4 chemokine receptor in relapsed\/refractory hodgkin lymphoma","volume":"144","author":"Grover","year":"2024","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.hoc.2025.12.008_bib18","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2009-03-209650","article-title":"T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model","volume":"113","author":"Di Stasi","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2025.12.008_bib19","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1046\/j.1365-3083.1998.00418.x","article-title":"Generation of the single chain antibody fragment conserves the idiotypic profile of the anti-CD30 monoclonal antibody HRS3","volume":"48","author":"Hombach","year":"1998","journal-title":"Scand J Immunol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.12.008_bib20","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1182\/blood-2021-146100","article-title":"Safety and efficacy profile of autologous CD30.CAR-T-cell therapy in patients with relapsed or refractory classical Hodgkin lymphoma (CHARIOT trial)","volume":"138","author":"Ahmed","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.12.008_bib21","doi-asserted-by":"crossref","first-page":"7496","DOI":"10.1182\/blood-2022-158869","article-title":"Updated results and correlative analysis: autologous CD30.CAR-T-Cell therapy in patients with relapsed or refractory classical hodgkin lymphoma (CHARIOT trial)","volume":"140","author":"Ahmed","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2025.12.008_bib22","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1182\/bloodadvances.2023012129","article-title":"CARs for Hodgkin: engine fine-tuning is in order","volume":"8","author":"Grover","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.hoc.2025.12.008_bib23","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/bloodadvances.2021005385","article-title":"Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma","volume":"6","author":"Voorhees","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.hoc.2025.12.008_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1268","article-title":"Memory stem T cells modified with a redesigned CD30-chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma","volume":"10","author":"Alvarez-Fern\u00e1ndez","year":"2021","journal-title":"Clin & Trans Imm"},{"issue":"6","key":"10.1016\/j.hoc.2025.12.008_bib25","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/mt.2016.63","article-title":"GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade","volume":"24","author":"Gargett","year":"2016","journal-title":"Mol Ther"},{"issue":"8","key":"10.1016\/j.hoc.2025.12.008_bib26","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J Clin Investig"},{"issue":"16","key":"10.1016\/j.hoc.2025.12.008_bib27","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1158\/1078-0432.CCR-13-2627","article-title":"Multifactorial t-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor\u2013transduced human t cells in solid tumors","volume":"20","author":"Moon","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.12.008_bib28","doi-asserted-by":"crossref","first-page":"12723","DOI":"10.1182\/blood-2022-156660","article-title":"Clinical activity of Anti-PD-1 therapy following CD30 CAR-T cell therapy in relapsed hodgkin lymphoma","volume":"140","author":"Voorhees","year":"2022","journal-title":"Blood"},{"issue":"S3","key":"10.1016\/j.hoc.2025.12.008_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70093_141","article-title":"141 | CD30 car-t in relapsed and refractory CD30+ lymphomas: long-term follow-up of a phase IB\/II clinical trial","volume":"43","author":"Reef","year":"2025","journal-title":"Hematol Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.12.008_bib30","doi-asserted-by":"crossref","first-page":"12728","DOI":"10.1182\/blood-2022-157131","article-title":"Phase 1b\/2 study of autologous CD30.CAR-T cells in combination with nivolumab in patients with relapsed or refractory classical hodgkin lymphoma after failure of frontline therapy (ACTION)","volume":"140","author":"Mei","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2025.12.008_bib31","article-title":"Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-hodgkin\u2019s lymphoma","volume":"13","author":"Junkuhn","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2025.12.008_bib32","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","article-title":"Na\u00efve T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers","volume":"9","author":"Das","year":"2019","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.hoc.2025.12.008_bib33","article-title":"Rejection resistant CD30.CAR-modified epstein-barr virus-specific T cells as an off-the-shelf platform for CD30+ lymphoma","volume":"32","author":"Quach","year":"2024","journal-title":"Mol Ther Oncol"},{"issue":"S2","key":"10.1016\/j.hoc.2025.12.008_bib34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/hon.3163_47","article-title":"OFF-THE-SHELF CD30.CAR-MODIFIED epstein-barr virus-specific T cells (CD30.CAR EBVSTS) provide a safe and effective therapy for patients with Hodgkin lymphoma (HL)","volume":"41","author":"Ramos","year":"2023","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.hoc.2025.12.008_bib35","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022018893","article-title":"5-Year Follow-Up supports curative potential of axicabtagene Ciloleucel in refractory large B-Cell lymphoma (ZUMA-1)","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2025.12.008_bib36","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.2023020854","article-title":"Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001","volume":"143","author":"Abramson","year":"2024","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2025.12.008_bib37","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.hoc.2025.12.008_bib38","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.hoc.2025.12.008_bib39","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.1158\/1078-0432.CCR-24-0830","article-title":"Metabolic tumor volume response after bridging therapy determines chimeric antigen receptor t-cell outcomes in large B-Cell lymphoma","volume":"30","author":"Hubbeling","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.hoc.2025.12.008_bib40","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.hoc.2025.12.008_bib41","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s00277-021-04560-6","article-title":"Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy","volume":"100","author":"Iacoboni","year":"2021","journal-title":"Ann Hematol"},{"issue":"16","key":"10.1016\/j.hoc.2025.12.008_bib42","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood.2024028274","article-title":"Can less differentiation drive CARs to success?","volume":"145","author":"Grover","year":"2025","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.hoc.2025.12.008_bib43","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"issue":"7996","key":"10.1016\/j.hoc.2025.12.008_bib44","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41586-023-06903-x","article-title":"Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling","volume":"625","author":"Alig","year":"2024","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.hoc.2025.12.008_bib45","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1158\/0008-5472.CAN-05-0100","article-title":"Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin\u2019s disease: potential for a prognostic factor","volume":"65","author":"Weihrauch","year":"2005","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.hoc.2025.12.008_bib46","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood-2018-08-870915","article-title":"Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study","volume":"133","author":"Hsi","year":"2019","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.hoc.2025.12.008_bib47","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1182\/bloodadvances.2025015837","article-title":"Serum TARC: a biomarker for early detection or exclusion of relapse in classic Hodgkin lymphoma","volume":"9","author":"Teesink","year":"2025","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.hoc.2025.12.008_bib48","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1080\/10428194.2022.2095623","article-title":"AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial","volume":"63","author":"Sasse","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"10.1016\/j.hoc.2025.12.008_bib49","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood.2019004701","article-title":"A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"136","author":"Bartlett","year":"2020","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.hoc.2025.12.008_bib50","first-page":"2125","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Orthod"},{"issue":"6","key":"10.1016\/j.hoc.2025.12.008_bib51","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/s41591-025-03640-8","article-title":"Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial","volume":"31","author":"Nieto","year":"2025","journal-title":"Nat Med"},{"issue":"S3","key":"10.1016\/j.hoc.2025.12.008_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70093_107","article-title":"107 | Results from the dose-finding part oF LuminICE-203 phase 2 study: ACIMTAMIG (AFM13) in combination with AlloNK (AB-101) in patients with relapsed\/refractory hodgkin lymphoma","volume":"43","author":"Maakaron","year":"2025","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.hoc.2025.12.008_bib53","author":"Shah"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2025.12.008_bib54","first-page":"7008","article-title":"Results from the completed dose-finding part of phase 2 study of the innate cell engager acimtamig (AFM13) in combination with AlloNK (AB-101) in relapsed or refractory classical Hodgkin lymphoma (LuminICE-203)","volume":"43","author":"Maakaron","year":"2025","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.hoc.2025.12.008_bib55","article-title":"Affimed. Affimed announces filing for the opening of insolvency proceedings","year":"2025","journal-title":"Affimed"},{"issue":"9","key":"10.1016\/j.hoc.2025.12.008_bib57","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1182\/blood-2001-12-0295","article-title":"Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma","volume":"100","author":"Borchmann","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.12.008_bib58","author":"Taylor"},{"key":"10.1016\/j.hoc.2025.12.008_bib59","series-title":"Form 20-F: annual report (Fiscal Year ended December 31, 2024)","author":"Genmab","year":"2025"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.12.008_bib60","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1182\/blood-2023-180926","article-title":"Safety and preliminary efficacy of sabestomig (AZD7789), an Anti-PD-1 and Anti-TIM-3 bispecific antibody, in patients with relapsed or refractory classical hodgkin lymphoma previously treated with Anti-PD-(L)1 therapy","volume":"142","author":"Mei","year":"2023","journal-title":"Blood"},{"issue":"S3","key":"10.1016\/j.hoc.2025.12.008_bib61","article-title":"S216: CD47\/PD-L1 bispecific antibody (IBI322) IN ANTI-PD-1 or PD-L1 treatment-resistant classical hodgkin lymphoma: a phase I study","volume":"7","author":"Zhang","year":"2023","journal-title":"HemaSphere"},{"issue":"16","key":"10.1016\/j.hoc.2025.12.008_bib62","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1182\/blood.2023020485","article-title":"Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade","volume":"142","author":"Mei","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.12.008_bib63","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/blood-2024-210053","article-title":"Final response and survival results from a phase II trial of pembrolizumab and entinostat in relapsed\/refractory Hodgkin lymphoma","volume":"144","author":"Stuver","year":"2024","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.hoc.2025.12.008_bib64","first-page":"1479","article-title":"Addition of low-dose decitabine to Anti\u2013PD-1 antibody camrelizumab in Relapsed\/refractory classical hodgkin lymphoma","volume":"37","author":"Nie","year":"2019","journal-title":"J Clin Orthod"},{"issue":"10","key":"10.1016\/j.hoc.2025.12.008_bib65","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1158\/1078-0432.CCR-21-0133","article-title":"Efficacy of decitabine plus Anti-PD-1 camrelizumab in patients with hodgkin lymphoma who progressed or relapsed after PD-1 blockade monotherapy","volume":"27","author":"Wang","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.hoc.2025.12.008_bib66","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002347","article-title":"Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed\/refractory Hodgkin lymphoma","volume":"9","author":"Liu","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"18","key":"10.1016\/j.hoc.2025.12.008_bib67","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1182\/blood.2024024487","article-title":"Epigenetic agents plus anti-PD-1 reprogram the tumor microenvironment and restore antitumor efficacy in Hodgkin lymphoma","volume":"144","author":"Nie","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.12.008_bib68","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1182\/blood-2023-182019","article-title":"Favezelimab in combination with pembrolizumab in patients with heavily pretreated anti-PD-1-Refractory classical hodgkin lymphoma: updated analysis of an open-label phase 1\/2 study","volume":"142","author":"Timmerman","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.12.008_bib69","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1182\/blood-2023-182128","article-title":"Favezelimab in combination with pembrolizumab in patients with Anti-PD-1-Naive relapsed or refractory classical hodgkin lymphoma: updated analysis of an open-label phase 1\/2 study","volume":"142","author":"Johnson","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.12.008_bib70","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1182\/blood-2024-203156","article-title":"TQB2223 in combination with penpulimab in patients with relapsed or refractory lymphoma: primary analysis of an open-label phase I study","volume":"144","author":"Cai","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.12.008_bib71","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1182\/blood-2024-203414","article-title":"Ipilimumab with and without nivolumab in patients with classic hodgkin lymphoma with progression after PD-1 blockade","volume":"144","author":"Merryman","year":"2024","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2025.12.008_bib72","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3026(20)30221-0","article-title":"Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1\/2 trial","volume":"7","author":"Diefenbach","year":"2020","journal-title":"Lancet Haematol"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2025.12.008_bib73","first-page":"7041","article-title":"Updated efficacy and safety results from the phase 2 study of timdarpacept in combination with tislelizumab in patients with classical Hodgkin lymphoma for whom prior anti\u2013PD-1 therapy failed","volume":"43","author":"Zhou","year":"2025","journal-title":"J Clin Orthod"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.12.008_bib74","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1182\/blood-2024-210689","article-title":"Pembrolizumab and involved site radiation therapy alone as an alternative to transplant in patients with localized failure following chemotherapy for hodgkin lymphoma: a prospective multicenter phase II study","volume":"144","author":"Dreyfuss","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.12.008_bib75","doi-asserted-by":"crossref","first-page":"4796","DOI":"10.1182\/blood-2024-207274","article-title":"Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma","volume":"144","author":"Gottschlich","year":"2024","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.hoc.2025.12.008_bib76","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1182\/blood.2024027782","article-title":"The immunotherapy real estate of Hodgkin lymphoma","volume":"145","author":"Steidl","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2025.12.008_bib77","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-025-01257-1","article-title":"Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers","volume":"15","author":"Voorhees","year":"2025","journal-title":"Blood Cancer J"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825001492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825001492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T21:25:23Z","timestamp":1773955523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858825001492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0889858825001492"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2025.12.008","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cellular and Novel Immunotherapies for Classic Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2025.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}